NCT05944016 - Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Chronic Kidney Failure in Children and Young Adults

Interventions

DRUG

Dapagliflozin

Dapagliflozin (standard dose 10 mg p.o. once daily)

DRUG

Placebo

Placebo (standard dose p.o. once daily)

Trial Locations (16)

10117

RECRUITING

Charite Berlin - Adults, Berlin

RECRUITING

Charite Berlin - Children, Berlin

20246

RECRUITING

Universitätsklinikum Hamburg-Eppendorf - Adults, Hamburg

20251

RECRUITING

Universitätsklinikum Hamburg-Eppendorf - Children, Hamburg

37075

RECRUITING

University Medicine Goettingen - Adults, Göttingen

RECRUITING

University Medicine Goettingen - Childrens Hospital, Göttingen

48149

NOT_YET_RECRUITING

Universitätsklinik Münster - Adults, Münster

RECRUITING

Universitätsklinikum Münster - Children, Münster

50937

RECRUITING

Universitätsklinik Köln - Adults, Cologne

RECRUITING

Universitätsklinik Köln - Children, Cologne

60316

RECRUITING

Clementine Kinderhospital, Frankfurt am Main

69120

RECRUITING

Universitätsklinikum Heidelberg - Children, Heidelberg

80336

RECRUITING

LMU Klinikum, München

81337

RECRUITING

v. Haunersches Kinderhospital, München

04103

RECRUITING

Universitätsklinik Leipzig - Children, Leipzig

RECRUITING

Universitätsklinikum Leipzig - Adults, Leipzig